Myhr KM - Search Results

1

Body mass index influence interferon-beta treatment response in multiple sclerosis.

Kvistad SS, Myhr KM, Holmøy T, Šaltytė Benth J, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Michelsen AE, Aukrust P, Ueland T, Sagen JV, Torkildsen Ø. Kvistad SS, et al. Among authors: myhr km. J Neuroimmunol. 2015 Nov 15;288:92-7. doi: 10.1016/j.jneuroim.2015.09.008. Epub 2015 Sep 26. J Neuroimmunol. 2015. PMID: 26531700 Clinical Trial.

2

[Multiple sclerosis].

Nyland H, Myhr KM. Nyland H, et al. Among authors: myhr km. Tidsskr Nor Laegeforen. 1995 Jun 30;115(17):2072-7. Tidsskr Nor Laegeforen. 1995. PMID: 7544032 Free article. Review. Norwegian.

3

Absence of HTLV-1 related sequences in MS from high prevalence areas in western Norway.

Myhr KM, Frost P, Grønning M, Midgard R, Kalland KH, Helland DE, Nyland HI. Myhr KM, et al. Acta Neurol Scand. 1994 Jan;89(1):65-8. doi: 10.1111/j.1600-0404.1994.tb01634.x. Acta Neurol Scand. 1994. PMID: 8178631

4

Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: design of a randomised, placebo-controlled, double blind trial in Norway.

Nyland H, Myhr KM, Lillås F, Smievoll AI, Riise T, Nortvedt M, Nilsen R. Nyland H, et al. Among authors: myhr km. Mult Scler. 1996 Jul;1(6):372-5. doi: 10.1177/135245859600100618. Mult Scler. 1996. PMID: 9345420 Clinical Trial.

5

Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.

Myhr KM, Riise T, Green Lilleås FE, Beiske TG, Celius EG, Edland A, Jensen D, Larsen JP, Nilsen R, Nortvedt MW, Smievoll AI, Vedeler C, Nyland HI. Myhr KM, et al. Neurology. 1999 Mar 23;52(5):1049-56. doi: 10.1212/wnl.52.5.1049. Neurology. 1999. PMID: 10102427 Clinical Trial.

6

Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients.

Nordvik I, Myhr KM, Nyland H, Bjerve KS. Nordvik I, et al. Among authors: myhr km. Acta Neurol Scand. 2000 Sep;102(3):143-9. doi: 10.1034/j.1600-0404.2000.102003143.x. Acta Neurol Scand. 2000. PMID: 10987373 Clinical Trial.

7

Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension.

Myhr KM, Riise T, Vedeler C, Nortvedt MW, Grønning R, Midgard R, Nyland HI. Myhr KM, et al. Mult Scler. 2001 Feb;7(1):59-65. doi: 10.1177/135245850100700110. Mult Scler. 2001. PMID: 11321195

8

Fc receptors for immunoglobulin G--a role in the pathogenesis of Guillain-Barré syndrome and multiple sclerosis.

Vedeler CA, Myhr KM, Nyland H. Vedeler CA, et al. Among authors: myhr km. J Neuroimmunol. 2001 Aug 30;118(2):187-93. doi: 10.1016/s0165-5728(01)00344-7. J Neuroimmunol. 2001. PMID: 11498253 Review.

9

No linkage or association of the nitric oxide synthase genes to multiple sclerosis.

Modin H, Dai Y, Masterman T, Svejgaard A, Sørensen PS, Oturai A, Ryder LP, Spurkland A, Vartdal F, Laaksonen M, Sandberg-Wollheim M, Myhr KM, Nyland H, Hillert J. Modin H, et al. Among authors: myhr km. J Neuroimmunol. 2001 Sep 3;119(1):95-100. doi: 10.1016/s0165-5728(01)00366-6. J Neuroimmunol. 2001. PMID: 11525805

10

Interleukin-10 promoter polymorphisms in patients with multiple sclerosis.

Myhr KM, Vågnes KS, Marøy TH, Aarseth JH, Nyland HI, Vedeler CA. Myhr KM, et al. J Neurol Sci. 2002 Oct 15;202(1-2):93-7. doi: 10.1016/s0022-510x(02)00246-0. J Neurol Sci. 2002. PMID: 12220699

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

314 results

Search Page